Biopharmaceutical company Incyte Corporation (NASDAQ: INCY) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 20.9% year on year to $1.27 billion. On the other hand, the company’s full-year revenue guidance of $4.86 billion at the midpoint came in 12.9% below analysts’ estimates. Its non-GAAP profit of $1.81 per share was 35.1% above analysts’ consensus estimates.

Is now the time to buy Incyte? Find out by accessing our full research report, it’s free.

Company Overview

Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer, Incyte (NASDAQ: INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics for cancer and inflammatory diseases.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Luckily, Incyte’s sales grew at a solid 15% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Incyte’s annualized revenue growth of 19.3% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated.

This quarter, Incyte reported robust year-on-year revenue growth of 20.9%, and its $1.27 billion of revenue topped Wall Street estimates by 4.7%.

Looking ahead, sell-side analysts expect revenue to grow 5.7% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is above average for the sector and implies the market is baking in some success for its newer products and services.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Adjusted Operating Margin

Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt, and taxes.

Incyte has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 23.5%.

Looking at the trend in its profitability, Incyte’s adjusted operating margin rose by 4.5 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company’s margin has increased by 5.6 percentage points on a two-year basis. These data points are very encouraging and show momentum is on its side.

This quarter, Incyte generated an adjusted operating margin profit margin of 26.7%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.

Incyte’s EPS grew at 19.4% compounded annual growth rate over the last five years, higher than its 15% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.

Diving into the nuances of Incyte’s earnings can give us a better understanding of its performance. As we mentioned earlier, Incyte’s adjusted operating margin was flat this quarter but expanded by 4.5 percentage points over the last five years. On top of that, its share count shrank by 6.8%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth.

In Q1, Incyte reported adjusted EPS of $1.81, up from $1.16 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. We also like to analyze expected EPS growth based on Wall Street analysts’ consensus projections, but there is insufficient data.

Key Takeaways from Incyte’s Q1 Results

It was good to see Incyte beat analysts’ EPS expectations this quarter. We were also glad its revenue outperformed Wall Street’s estimates. On the other hand, its full-year revenue guidance missed. This outlook seems to be weighing on shares, and the stock traded down 2.8% to $93.00 immediately after reporting.

So should you invest in Incyte right now? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).